AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 122 min read$MIRM

Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 results for LIVMARLI in treating ultra-rare cholestatic liver diseases, meeting primary endpoints. The drug improved itch severity and reduced serum bile acids. Mirum plans an FDA filing in 2027. Shares rose 5.73% on the news.

Original reporting
rttnews.com
Published Oct 12, 2026, 1:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027 — source image
Source · rttnews.com
Decision brief

The 30-second read

$MIRMBullishHigh
01

Why it matters

The Phase 3 data provide a clear efficacy signal, supporting label expansion and potentially boosting revenue streams.

02

Market read

Positive trial results and a forthcoming FDA filing create immediate upside for MIRM and may lift peer biotech valuations.

03

What to watch

Regulatory review risk and competition from other IBAT inhibitors could limit market share.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Mirum Pharmaceuticals focuses on rare cholestatic liver diseases; LIVMARLI is already approved for Alagille syndrome and PFIC.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum Pharmaceuticals announced positive Phase 3 EXPAND trial results for LIVMARLI and plans an FDA filing in 2027, driving a 5.73% stock rise.

Expected impact

upward pressure as investors price in potential label expansion and future revenue.

Evidence & confidence

Phase 3 success is material for a biotech; the stock already jumped on the news, indicating strong market reaction.

Market effects

Sector

Rare‑disease biotech sector may see increased investor interest and higher valuations for companies with late‑stage pipelines.

Regional

U.S. biotech market gains from the trial news.

Global

Potential global interest as LIVMARLI could be approved for additional ultra‑rare liver diseases worldwide.

Counterpoint

What could challenge this read

The filing is not expected until 2027; long timeline may dampen near‑term upside despite short‑term rally.

Key entities

  • Company
    Mirum Pharmaceuticals

    Biopharma developing treatments for ultra‑rare liver diseases.

  • Drug
    LIVMARLI (maralixibat)

    IBAT inhibitor currently approved for cholestatic pruritus.

Read at source← All news

StoryMirum Pharmaceuticals reports positive Phase 3 EXPAND trial results for LIVMARLI

Related articles

OCT 12
$MIRMHighAI 8/10

Baird reiterates Mirum Pharmaceuticals stock rating on trial success

Baird reiterated an Outperform rating and $130 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for maralixibat. The study met primary and secondary endpoints, with 50% of patients having biliary atresia. The company reported 44% revenue growth over the last year and is valued at $5.41 billion. Analysts revised earnings upwards, with price targets ranging from $118 to $195.

investing.com2 min
OCT 12
$MIRMHighAI 9/10

Mirum’s maralixibat meets primary endpoint in liver disease trial

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 trial results for maralixibat in treating cholestatic pruritus in rare liver diseases. The drug met its primary endpoint, showing significant improvement in itch severity and serum bile acids reduction compared to placebo. Mirum plans to submit a supplemental New Drug Application in the U.S. in early 2027.

investing.com2 min
OCT 12
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM) Phase 3 EXPAND Meets Primary, All Secondary Endpoints

Mirum Pharmaceuticals (MIRM) announced its Phase 3 EXPAND study of LIVMARLI met primary and secondary endpoints, including biliary atresia analyses, with no new safety concerns. The company plans a U.S. supplemental New Drug Application in H1 2027. According to the company, this extends LIVMARLI's potential beyond ALGS and PFIC to other ultra-rare cholestatic pruritus conditions.

tradingview.com1 min